SEC Form 4 · accession 0001232524-16-000319
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen L. Smith
Officer — Global Head of R&D and CMO
Period of report
Aug 12, 2016
Accepted (ET)
Aug 12, 2016 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Aug 12, 2016 | P | 607 | $137.0976 | A | 14,181 | D | |
| Ordinary Shares | Aug 12, 2016 | P | 1 | $137.2645 | A | 14,182 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.